Erratum to: PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury

Documenti analoghi

• PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury
  di: Hammond, Flora M., et al.
  Pubblicazione: (2016)
• Dextromethorphan/quinidine sulfate (Zenvia) for Pseudobulbar Affect
  di: Rosen, Howard
  Pubblicazione: (2008)
• Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affect
  di: Schoedel, Kerri A, et al.
  Pubblicazione: (2014)
• Review of Dextromethorphan 20 mg/Quinidine 10 mg (NUEDEXTA(®)) for Pseudobulbar Affect
  di: Pioro, Erik P.
  Pubblicazione: (2014)
• An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions
  di: Pattee, Gary L., et al.
  Pubblicazione: (2014)